Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ility and edema and prevent the inappropriate growth of new blood vessels in the retina in patients with CRVO.

About VEGF Trap-Eye

VEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  VEGF Trap-Eye is a specific and highly potent blocker of these growth factors.  VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Bayer HealthCare and Regeneron are collaborating on the global development of VEGF Trap-Eye for the treatment of the neovascular form of age related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011. Bayer plans to file regulatory submissions in Europe in the second quarter of 2011.

In April 2011, Bayer HealthCare and Regeneron announced the initiation of a Phase 3 program in DME.

Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the companies will share equally the profits from any future sales of VEGF Trap-Eye.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, disease
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... leukemia is a malignant condition characterized by increased production ... first affects B-lymphocytes and then it can spread to ... mostly at later stages because of the slow buildup ... disease, the malignancy spreads to the spleen, liver, and ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has ... China (Basel, Switzerland - November 26-27, 2015)" conference to ... detailed overview of the key areas of pharmaceutical regulatory affairs ... , Macau and ... All important aspects of gaining and maintaining a successful Marketing ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... , SAN FRANCISCO , May 18 ... demonstrated patients treated with a standard or low dose of ... in how often they were awakened at night by hot ... presented today at the 58th Annual Clinical Meeting of the ...
... NANJING , China, May 18 /PRNewswire-Asia/ -- ... ), a leading pharmaceutical company,specializing in the development, manufacturing, and ... preliminary,unaudited financial results for the quarter ended March 31, ... -- Total revenue was RMB458.7 million (US$67.2 million) for ...
Cached Medicine Technology:New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 2Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 3Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 4Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 5Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 6Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 7Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 8Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 9Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 10Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 11Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results 12
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we ... with the traditional health care model, where the primary care physician dictates and the ... want to become educated about their health issues and empowered to choose their own ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of prostate cancer ... seven men will be diagnosed with prostate cancer during their lifetime. While only one man ... of every 10 men by age 65, according to the American Cancer Society. ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will be hosting ... this episode, James Earl Jones will introduce a segment that discusses why it is ... how workplace wellness can be fostered in any working environment. , Employers are out ...
(Date:9/3/2015)... FLORIDA (PRWEB) , ... September 03, 2015 , ... ... of the highest-regarded health professionals out there. His perspective on internal medicine keeps patients ... stay happy and healthy is important regardless of the season, but even more so ...
(Date:9/3/2015)... COLO (PRWEB) , ... September 03, 2015 , ... Fashion ... the very beginning of the most recent episode of the hit ABC series ... didn’t fit the image of her industry. She provided herself with the motivation to ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3
... from living in two-parent families may actually be due to ... married. A new study finds that children who who ... do as well as those in married households in terms ... studies that show an advantage for children who grow up ...
... , , MONROE, Mich., ... center are joining forces to bring world-renowned cancer services to ... Health System of Toledo, and the Barbara Ann Karmanos Cancer ... will bring innovative, state-of-the-science cancer care to Monroe and the ...
... , Channels Extend Their Pledge for the ... , , LOS ANGELES and NEW YORK, Aug. 31 ... partnership with FC Barcelona and Malaria No More to end malaria deaths through ... campaign during Fox Football Fone-In, Fox Soccer Channel,s weekly call-in ...
... , WALTHAM, Mass., Aug. 31 ... dangerously hot weather conditions, Mobile Sports, Inc. (MSI) today announced ... athletes, parents of athletes, coaches, and athletic trainers the tools ... serious heat-related illnesses. , , ...
... Aug. 31 Mederi Therapeutics Inc. announces the US release ... Secca Therapy is a minimally invasive procedure for a debilitating ... both young and old. Secca therapy delivers radiofrequency (RF) energy ... muscles, producing better bowel control and reducing the symptoms of ...
... ... and Careers Division , ... York (PRWEB) August 31, 2009 -- The education and technology company Pearson today ... of its Professional & Career business., , , , ,Pearson,s Health Science and Careers division ...
Cached Medicine News:Health News:Family stability may be more crucial than 2 parents for child success 2Health News:Family stability may be more crucial than 2 parents for child success 3Health News:Three Health Institutions Join Forces to Bring World-Renowned Cancer Care to Monroe, Michigan 2Health News:Three Health Institutions Join Forces to Bring World-Renowned Cancer Care to Monroe, Michigan 3Health News:Three Health Institutions Join Forces to Bring World-Renowned Cancer Care to Monroe, Michigan 4Health News:Fox Soccer Channel and Fox Sports en Espanol Renew 'Every Goal Saves A Life' Campaign With Malaria No More 2Health News:Fox Soccer Channel and Fox Sports en Espanol Renew 'Every Goal Saves A Life' Campaign With Malaria No More 3Health News:Fox Soccer Channel and Fox Sports en Espanol Renew 'Every Goal Saves A Life' Campaign With Malaria No More 4Health News:New Technology Helps Athletes Prevent Dehydration and Heat-Related Illness 2Health News:Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US 2Health News:Pearson Announces Leah Jewell as President of Health Science and Careers Division 2Health News:Pearson Announces Leah Jewell as President of Health Science and Careers Division 3
The cemented hip joint prosthesis system....
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: